More than $100 million in opioid settlement funds sits unspent in New Mexico, years after courts ordered payments to address the crisis. Local governments cite workforce shortages, procurement hurdles, and long-term sustainability concerns as reasons the money hasn’t reached treatment programs.
Where the money is—and isn’t
The New Mexico Office of the State Auditor released a transparency review showing that as of fiscal year 2025, local governments held over $100 million from opioid settlements. Many reported little or no spending on prevention, treatment, or recovery services.
Officials described capacity constraints as a key barrier. Procurement rules, designed to prevent waste, can slow down contracts for services like naloxone distribution or peer support networks.
A 2023 state law created dedicated opioid settlement funds and a framework to ensure the money goes toward remediation. But coordination remains a challenge. Agencies, local governments, and providers are still figuring out how to track spending, measure outcomes, and communicate progress to the public.
The auditor’s office will continue publishing reports on who is spending, what’s working, and where bottlenecks persist. The goal isn’t just to move money—it’s to turn it into fewer overdose deaths.
Related: Hospitals test wristbands to cut childbirth risks
Lessons from a stalled system
New Mexico’s experience mirrors struggles in other states. Securing settlement dollars was only the first step. Now, governments must build the systems to spend it effectively.
Some local officials have argued that the funds should be released in smaller, more flexible amounts to avoid overwhelming understaffed agencies. Others have pushed for state-level technical assistance to help rural counties design programs. A few have suggested creating regional coalitions to share resources and expertise.
This isn’t the first time public health funding has faced implementation delays. After the 2009 tobacco settlements, many states diverted money to unrelated budget gaps instead of anti-smoking programs. The opioid crisis, however, has drawn more scrutiny. Advocates and families of those lost to overdoses have demanded transparency, making it harder for governments to sit on the funds indefinitely.
The core question isn’t just where the money is. It’s whether states can build the capacity to turn it into measurable public health gains. New Mexico’s auditor has promised to keep reporting on progress—or the lack of it.
In the meantime, the funds remain in limbo, a reminder that even the best-funded plans can stall without the right systems in place.
